chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Fatigue, weight loss of 16 pounds, bilateral leg pain.  8/22/2008 MR received from PCP. OV 5/21/2008 for c/o 16lb wt loss over the past 6 weeks and fatigue. ROS (+) for headache, blurred vision, orthostatic hypotension, heart palpitations, muscle cramps, diarrhea after eating full meals, bilateral leg aches and weakness, dizziness on arising, decreased appetitite.  Pt describes not feeling fun and decreased participation in activities.  Feels cold and having difficulty with menstual cycles. PE (+) for nasal congestion. Assessment:  Weight loss-sinusitis vs depression vs chronic inflammatory process. OV 7/10/08 still c/o muscle weakness in upper thighs since 3rd Gardasil.  Other sx improving.
My hands were weak and tingly as if I had nerve damage. I wasn't able to open a bottle of water. I had a hard tome gripping things. My hands felt right and sore for days after the 1st shot. And again with the 2nd shot.  Also, after the 2nd shot the next day I had a strange sharp  chest pain and other odd feelings that lasted on and off for couple of hours.
Pain in the back that spread to below the front right rib. Pain resulted in shortness of breath and pain on inhalation.
Had 18 month boosters 3/13/07. On the evening of 3/14/07, red arm, low grade temp seen office diagnosed with cellulitis. Keflex 125/5 TID x 10 C
Upper right back pain; Like upper flank pain; Chills; Takes my breath away; This is a spontaneous report from a non-contactable nurse, the patient. A 43-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 16Apr2021 at 19:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included ascorbic acid (VITAMIN C), vitamin b complex (B COMPLEX), magnesium (MANUFACTURER UNKNOWN), calcium (MANUFACTURER UNKNOWN) and multi (MANUFACTURER UNKNOWN); all for unknown indications from an unknown date and unknown if ongoing. The patient previously received amoxicillin (MANUFACTURER UNKNOWN) for unknown indication on an unknown date and experienced drug allergy. On 18Apr2021 at 19:00, 48 hours after vaccination, the patient experienced upper right back pain and it went bad overnight, worsening through day 3 post-vaccination. Like upper flank pain which takes the breath away and chills but no fever. It was reported that the patient might go to emergency room. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events upper right back pain, upper flank pain which takes the breath away and chills was not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
Gave 2nd DTAP, 2nd Polio, 2nd MMR and 3rd Hep-B.
pt recvd vax; throat was sore & "closed up" about 2-3 hrs after inject; no dyspnea then approx 2 hrs later, exp dizziness; diaphoretic; faintness;
Shot received morning of 10/21. Mild headache developed evening of 10/21. Morning of 10/22, headache became severe and fever developed. Began at 99F and climbed throughout day; reached 103.6 overnight 10/22. Chills, weakness, and very severe headache. Fever broke morning of 10/23, but severe headache continued. Nausea and vomiting during day 10/23. Severe headache and nausea continued overnight and through 10/24. Fluids, ice, and NSAIDs did not provide any relief from headache.
HAS A SORE ARM AFTER THE INJECTION FROM A FEW WEEKS AGO; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805022 expiry: UNKNOWN) dose was not reported, administered on 08-MAR-2021 on left arm for prophylactic vaccination. No concomitant medications were reported. On 08-MAR-2021, the subject experienced has a sore arm after the injection from a few weeks ago. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from has a sore arm after the injection from a few weeks ago. This report was non-serious.
Information has been received from a registered nurse concerning a patient who on 16-OCT-2008 was vaccinated PO with a dose of ROTATEQ.  It was reported that immediately after administration of the vaccine the patient had turned and coughed (also reported as the child spit).  It is unknown if the patient sought medical attention.  A product quality complaint was not involved.  This is one of several reports received from the same source.  Additional information has been requested. This is in follow-up to report (s) previously submitted on 11/14/2008. No further information is available.
Patient admitted on 9/6/2021 for RUQ pain and itching.  She received betamethasone for fetal lung maturity. Magnesium sulfate was stopped because labs were reassuring and BP normalized. Bile acids were sent. She received hydroxyzine for itching. On hospital day #2 she was feeling better and requested discharge to home. C-Section delivery on date. ED visit and Hospital admissions within 6 weeks of receiving the COVID vaccine
Pregnant at 32 weeks and 35 weeks for doses of vaccine, pregnancy was uncomplicated prior to vaccination. At 36 weeks diagnosed with intrauterine growth restriction and placental insufficiency necessitating induction of labor.
On 09/22/2001 the patient broke out with approximately 3 large vesicles and complained of pruritus. On 09/24/2001 smaller vesicles appeared on the patient's back, legs, stomach, face and chest. The patient's fever was up to 102.7F. The patient had red, watery eyes with exudation from his eyes.
passing out; Vomiting; diarrhea; This is a spontaneous report from a contactable consumer (patient). A non-pregnant 17-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), dose 1 via an unspecified route of administration, administered in the left arm on 13Apr2021 at 13:45 (Batch/Lot Number: Ew0161) at 17-years-old as a single dose for COVID-19 immunization. The patient did not receive any other vaccine within four weeks of the suspect vaccine. The patient's medical history was reported as none (no known allergies). The patient did not have COVID prior to the vaccination. Concomitant medications included ethinylestradiol, ferrous fumarate, norethisterone acetate (LO LOESTRIN FE) taken for an unspecified indication, start and stop date were not reported. On 14Apr2021 at 13:15, the patient experienced passing out (medically significant), vomiting (non-serious), and diarrhea (non-serious). The clinical outcome of the events was recovering. The patient was not tested for COVID post vaccination.
Fever; Light headed; Pain in neck; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever), DIZZINESS (Light headed) and NECK PAIN (Pain in neck) in a 24-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030B21A) for COVID-19 vaccination.     No medical history was provided by the reporter.     On 09-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Apr-2021, the patient experienced PYREXIA (Fever), DIZZINESS (Light headed) and NECK PAIN (Pain in neck). On 10-Apr-2021, PYREXIA (Fever) had resolved, DIZZINESS (Light headed) outcome was unknown. On 13-Apr-2021, NECK PAIN (Pain in neck) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment details were not provided.   This case was linked to MOD-2021-114455 (Patient Link).
patient called to report she was diagnosed with cellulitis after receiving her 2nd dose of COVID-19 (Moderna) vaccine.. She went to the emergency room and was treated with antibiotics.
received 1st moderna vaccine on 4/7/21.; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (received 1st moderna vaccine on 4/7/21.) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (received 1st moderna vaccine on 4/7/21.). At the time of the report, PRODUCT DOSE OMISSION ISSUE (received 1st moderna vaccine on 4/7/21.) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported. Treatment Medications were not provided by the reporter.
weak; dizzy; This spontaneous case was reported by a consumer and describes the occurrence of ASTHENIA (weak) and DIZZINESS (dizzy) in a 73-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011A21A) for COVID-19 vaccination.     Concurrent medical conditions included Smoker.    On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Mar-2021, the patient experienced ASTHENIA (weak) and DIZZINESS (dizzy). At the time of the report, ASTHENIA (weak) and DIZZINESS (dizzy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  No treatment medications were provided by the reporter.
Ulcerative colitis flare and pancreatitis. Started developing abdominal pain 3 days after COVID vaccine that progressively worsened over 1 week. Then developed a fever and was seen in the ED when pancreatitis and colitis flare were diagnosed. At the time, I was receiving mesalamine, which was stopped. Started on clear liquid diet and symptoms improved within 24 hours. Discharged home on Uceris and low fat diet.
he was not feeling well for 2 days after the shot; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (he was not feeling well for 2 days after the shot ) in a 63-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Apr-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-May-2021, the patient experienced MALAISE (he was not feeling well for 2 days after the shot ). On 23-May-2021, MALAISE (he was not feeling well for 2 days after the shot ) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant and treatment medications were provided   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 30-May-2021: Follow-up information received contains no significant information
I exp muscle aches, joint pain, headaches, fever (101.4) and really bad chills.The headache was bordered on a migraine level.
24 hrs after immunization, left arm very swollen, hard, warm, itchy per mom. To ER given Benadryl, plus another medication.
body aches; hips were hurting; lost the sense of smell; pressure behind her eyes; stuffy nose; Headache; sore arm; felt a little feverish/It was a little elevated; feel as bad as she did; This is a spontaneous report from a contactable consumer (patient) via Medical information team. A 57-year-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number: EN6200), via an unspecified route of administration, administered in Arm Left on 18Feb2021 16:00 (age at the vaccination 57-year-old) as DOSE 1, SINGLE for covid-19 immunisation. Medical history included type 2 diabetes mellitus from Jul2020 to an unknown date and high blood pressure. Concomitant medications included metformin and metoprolol for high blood pressure. Patient had the Pfizer shot on 18Feb2021 which was last Thursday. The next day, 19Feb2021, she had a sore arm. Since patient developed stuffy nose and headache on 21Feb2021, body aches on 25Feb2021, lost sense of smell on 24Feb2021, patient also had pressure behind the eyes on 23Feb2021, patient felt a little feverish, but it did not register as a fever on an unspecified date in Feb2021. It was a little elevated. on day seven she had body aches. Specifically, both hips were hurting on 25Feb2021 It was achy like she had stretched too much. Today she feels a little better. Patient still has stuffiness, body aches, and still cannot smell. She does not feel as bad as she did on an unspecified date in Feb2021. Therapeutic measures were taken as a result of all events. The patient underwent lab tests and procedures which included feverish: little elevated on Feb2021, glycosylated haemoglobin (A1C): in the fives (numbers have been pretty good. A1C is in the fives), weight: about 160 lbs on an unspecified date. The outcome of the events stuffy nose, lost the sense of smell, body aches were not recovered, hips were hurting and feel as bad as she did was recovering and unknown for another events.  No follow-up attempts are possible. No further information is expected.
Patient received Pfizer vaccine, was sitting in observation at 14 minutes in reported (1104) feeling "heart beating fast, warm, throat feels funny"    Taken to ED for observation.  Appeared anxious, HR 119-130.  Pt without dib, throat swelling/ face swelling, itching, rash.
Child received immunizations on 2/07/13 at clinic. Father then took child to another clinic on 02/18/13 and child got vaccines again. Father stated "Did not show vax" that child had had vaccine - child had break out blisters head to toe and fever.
hives; lips and eyes are swollen; lips and eyes are swollen; measles-like red bumps on legs and hips; This is a spontaneous report from a contactable consumer (patient). This is the second of two reports.   A 50-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; solution for injection, Lot Number: EW0171) via an unspecified route of administration in the arm left on 02May2021 at 10:45 (at the age of 50-year-old) as a DOSE 2, SINGLE for COVID-19 immunisation. The patient was not pregnant at the time of vaccination. Medical history included Hashimoto's disease and anxiety. Concomitant medications included levothyroxine sodium (LEVOTHYROXIN), escitalopram oxalate (LEXAPRO), progesterone (MANUFACTURER UNKNOWN) and estrogen (MANUFACTURER UNKNOWN); all from unknown date for unspecified indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the arm left on 11Apr2021 at 10:45 (at the age of 50-year-old) as a DOSE 1, SINGLE for COVID-19 immunisation and experienced hives and penicillin on unknown date for unspecified indication and experienced diarrhoea, not allergic, just intolerant. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02May2021, the patient experienced hives, lips and eyes are swollen and measles-like red bumps on legs and hips. It was reported that the hives did not occur before four hours after second shot. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutics measures were taken as a result of reported events and treatment included with unspecified allergy medication. The clinical outcome of the events was recovering.  No follow-up attempts are needed. No further information is expected.
Mild feeling of throat constricting; dizziness; palpitations; Left arm sore; Circular rash next to injection site; This is a spontaneous report from a contactable other hcp (patient). A 52-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot Number: ELO140), via an unspecified route of administration in left arm on 06Jan2021 14:30 at single dose for COVID-19 immunization. Medical history included high blood pressure and brachial radial puritis. Concomitant medication included metoprolol succinate (TOPROL) and estrogens conjugated (PREMARIN). No COVID prior vaccination. No other vaccine in four weeks. The patient experienced mild feeling of throat constricting, dizziness, and palpitations, left arm sore, Circular rash next to injection site on 06Jan2021 14:45 (for about 20 minutes), left arm sore for about 4 days. No treatment received. No COVID tested post vaccination. The outcome of events was recovered in Jan2021.
Day 1 - Evening after vaccination: Neck, shoulder and headache - left (injection) arm sore/tender. Day 2: Neck, shoulder and headache unresponsive to standard dosing of acetaminophen, general lethargy, low body temp (97.7f). Day 3: Early AM (02:30) Onset of sweating and dizziness upon rising to use bathroom - stumbled back to bed with difficulty.  Balance of day; continued neck, shoulder and headache with only minor relief from acetaminophen, body temp still at 97.6f. Day 4-9: Continued neck, shoulder and headache becoming decreasingly intense, no longer taking acetaminophen, body temp remains in the 97.7f range where my body temp is normally around 98.6f.
This is a spontaneous report obtained from a contactable consumer (patient). A 50 year-old female patient of an unspecified race and ethnicity received PREVNAR 13 on an unknown date, at single dose, for immunization. Relevant medical history and concomitant medications were unknown. On an unspecified date, after the vaccination, the patient experienced shoulder pain. Clinical outcome was unknown at time of this report. No follow-up attempts possible. No further information expected.
I exposed to COVID-19 on June 03, 2022. I had a few symptoms on June 5, 2022 but they were not major, on Monday June 6, 2022 I started feeling unwell and took a home COVID-19 Test that came back positive. I called my doctor and made an appointment to go in and confirm my test results. He prescribed Paxlovid that I started taking that day. I am feeling better despite feeling a little tired and still having a bit of congestion.
Two days after receiving second dose of fizer COVID-19 vaccine at a vaccine event patient admitted to hospital after fall and presumed seizure: diagnosed with brain glioma.
Report fever, body aches, HA. Treatment: Tylenol, Outcome:  Moderate improvement of symptoms .  Does not interfere with ADLs.
the vaccine was expired at the time it was administered. Exp: date 03/21 called Pfizer Case number 00232165, after reading information sent to me, there is no BUD. I spoke with patients mother 05/05/2021 she is aware the vaccination will not count toward series and will not be able to administer until 30 days past 05/03/2021. She was very nice did not say he was having any issues but will let patient know and either he or his mother will call.
rash in back of neck p/2nd shot (pt has completed four shots/rt arm);rash still present;
pt recv vax 26OCT96 pain & redness @ site of inj that evening;Sunday pain was in neck, head & back;notified hlth dept on 28OCT96 & told to see PMD if problem persists;
My supra ventricular tachycardia (SVT) was brought on after I got my covid vaccinations. I have not had episodes of SVT until I received ,my covid vaccinations. Since my SVT episodes have started they have been persistent. The episodes were so bad that I was hospitalized on May 18th 2022 and will be needing surgery.
The day following the injection, I started getting sharp shooting electrical pain in my right arm (NOT the injection arm).  And then about 11pm on the following day (27 hours following the injection), I started forming hive clusters on my right arm. The hives were on my entire arm but they were especially focused on the front and back of my elbow.
I was informed by the pharmacist that she had injected me with an expired vaccine. It had been more than 6 hours since the vaccine was thawed.
guillain-barre; was vaccine injured from the swine flu shot; Initial information was received on 18-Nov-2022 regarding an unsolicited valid  serious case received from a other health professional.  This case involves a with unknown demographics patient who had guillain-barre and was injured from the Influenza vaccine.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect Influenza vaccine (produced by unknown manufacturer) (with unknown strength, dose, route, administration site, lot number and expiration date) for prophylactic vaccination.  On an unknown date the patient had guillain-barre (guillain-barre syndrome) and injured (injury) (unknown latency) following the administration of Influenza vaccine.  It was reported as: Also my aunt was vaccine injured from the swine flu shot. One of the unfortunate ones that it ended up with Guillain-Barre. She never recovered and her life was very limited with the neurological disease.  Action taken: Not applicable.  Corrective treatment: Not reported for both the events.  Outcome: Unknown for both the events.  Seriousness criteria: Medically significant for the event guillain-barre.; Sender's Comments: Sanofi company comment dated 23-Nov-2022: This case involves a with unknown demographics patient who had guillain-barre syndrome and was injured from the swine Influenza vaccine. A significant temporal relationship cannot be established due to lack of information on event onset date and vaccination date. Case will be reevaluated post further update on concurrent condition during vaccination, underlying diseases excluding alternative etiologies for the reported events, which will preclude a comprehensive assessment of this case. Based upon the reported information, the role of the suspect vaccine cannot be assessed.
hard close to the injection site; warm to the touch close to the injection site; Red rash close to the injection site; Muscle pain; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (warm to the touch close to the injection site), VACCINATION SITE INDURATION (hard close to the injection site), MYALGIA (Muscle pain) and VACCINATION SITE RASH (Red rash close to the injection site) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026l20a) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Jan-2021, the patient experienced MYALGIA (Muscle pain). On 24-Jan-2021, the patient experienced VACCINATION SITE WARMTH (warm to the touch close to the injection site) and VACCINATION SITE RASH (Red rash close to the injection site). On an unknown date, the patient experienced VACCINATION SITE INDURATION (hard close to the injection site). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. On 19-Jan-2021, MYALGIA (Muscle pain) had resolved. At the time of the report, VACCINATION SITE WARMTH (warm to the touch close to the injection site), VACCINATION SITE INDURATION (hard close to the injection site) and VACCINATION SITE RASH (Red rash close to the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Concomitant medications were provided